top of page

FCI Professorship for PROXIDRUGS member Manuel Kaulich

InnoTECH scientist Manuel Kaulich was appointed as FCI professor for autophagy in tumor pathogenesis as part of the LOEWE Center Frankfurt Cancer Institute (FCI). The FCI was inaugurated in 2019 as a joint endeavor between Goethe University Frankfurt, Georg-Speyer-Haus, Max Planck Institute for Heart & Lung Research and Paul-Ehrlich-Institut. It is funded by the Hessian Ministry of Higher Education, Research and the Arts and dedicated to investigating molecular mechanisms of therapeutic responses in tumors and development of Individual tumor therapies.

Manuel Kaulich was trained at University of Lübeck and obtained his PhD from Max Planck Institute of Biochemistry in Martinsried (Germany) and Biocenter Basel (Switzerland). He spent several years in the lab of Steven F. Dowdy at the University of California in San Diego, USA for his postdoctoral studies. Since December 2015, he was an independent group leader at the Institute of Biochemistry II at the Medical Faculty of the Goethe University Frankfurt, Germany.




Comments


bottom of page